We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > V920

News List

FDA accepts Biologics License Application for V920 Ebola vaccine europeanpharmaceuticalreview
September 20, 2019
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
$23m aid announced for Ebola vaccine manufacture europeanpharmaceuticalreview
August 23, 2019
The US HHS has committed to a contribution to help Merck manufacture its investigational V920 vaccine for the treatment of Ebola.
Merck & Co begins US filing of Ebola vaccine pharmaphorum
December 11, 2018
Merck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as V920, after the FDA said it could represent a breakthrough in treatment.